首页 / 院系成果 / 成果详情页

Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations 会议论文 期刊论文

编号：

1FCDF095A4224EE31E3F05C6391E0594
作者：

Wang, J.#;Zhao, J.;Fang, J.;Yu, Y.;Chu, Q.;Li, X.;Chen, J.;Liu, Z.;Zhang, L.;Wu, L.;Zhuang, W.;Li, X.;Zhao, Y.;Xing, L.;Liu, L.;Bai, C.;Dong, X.;Song, Q.;Wan, R.;Fang, X.
作者单位：

[Wang, J.; Wan, R.] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China.
[Zhao, J.] Peking Univ Canc Hosp & Inst, Dept Thorac Med Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China.
[Fang, J.] Peking Univ Canc Hosp, Thorac Med Oncol Dept 2, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.
[Yu, Y.] Harbin Med Univ Canc Hosp, Dept Resp Med, Harbin, Peoples R China.
[Chu, Q.] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China.
[Li, X.] Capital Med Univ, Beijing Tiantan Hosp, Comprehens Oncol Ctr, Beijing, Peoples R China.
[Chen, J.] Fudan Univ, Dept Radiotherapy, Shanghai Canc Ctr, Shanghai, Peoples R China.
[Liu, Z.] Capital Med Univ, Beijing Chest Hosp, Med Oncol, Beijing, Peoples R China.
[Zhang, L.] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Pulm & Crit Care Med, Beijing, Peoples R China.
[Wu, L.] Cent South Univ, Xiangya Sch, Thorac Med Dept 2, Hunan Canc Hosp,Affiliated Canc Hosp, Changsha, Peoples R China.
[Zhuang, W.] Fujian Canc Hosp, Thorac Med Oncol, Fuzhou, Peoples R China.
[Li, X.] Zhengzhou Univ, Oncol Dept, Affiliated Hosp 1, Ward 2, Zhengzhou, Peoples R China.
[Zhao, Y.] Zhengzhou Univ, Dept Resp, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China.
[Xing, L.] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China.
[Liu, L.] Shandong Univ, Med Oncol Dept, Qilu Hosp, Jinan, Peoples R China.
[Bai, C.] Peking Union Med Coll Hosp, Med Oncol, Beijing, Peoples R China.
[Dong, X.] Huazhong Univ Sci & Technol, Union Hosp, Thorac Oncol Dept, Canc Ctr,Union Hosp,Tongji Med Coll, Wuhan, Peoples R China.
[Song, Q.] Wuhan Univ, Canc Ctr, Renmin Hosp, Hubei Gen Hosp, Wuhan, Peoples R China.
[Fang, X.] Zhejiang Univ, Dept Med Oncol, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China.
语种：

英文
会议名称：

ANNALS OF ONCOLOGY
收录：
推荐引用方式
GB/T 7714：

Wang J.,Zhao J.,Fang J., et al. Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations [J].ANNALS OF ONCOLOGY,2024,35:S808-S808.
APA：

Wang J.,Zhao J.,Fang J.,Yu Y.,&Fang X..(2024).Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations .ANNALS OF ONCOLOGY,35:S808-S808.
MLA：

Wang J., et al. "Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations" .ANNALS OF ONCOLOGY 35(2024):S808-S808.
入库时间：

4/1/2025 12:06:14 PM
更新时间：

4/1/2025 12:06:14 PM

浏览次数：5  下载次数：0

分享到：

浏览次数：5

下载次数：0

打印次数：0

Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations 会议论文 期刊论文

Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations 会议论文期刊论文